Endurance (Cayman) Ltd Svf Sells 466,242 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Key Points

• Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology at an average price of $6.05, totaling approximately $2.82 million, resulting in a 2.90% decrease in their holdings.
• Vir Biotechnology’s stock is currently trading at $6.04 with a market cap of $839.08 million, having a 52-week range of $4.16 to $14.45.
• The company reported a quarterly earnings miss with an EPS of ($0.80), which was $0.08 below expectations, and a revenue decline of 60.5% year-over-year.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 466,242 shares of the business's stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $6.05, for a total value of $2,820,764.10. Following the completion of the sale, the insider owned 15,621,369 shares in the company, valued at $94,509,282.45. This represents a 2.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.60, for a total value of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.69, for a total value of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.56, for a total value of $2,503,901.52.

Vir Biotechnology Stock Down 0.2%

NASDAQ VIR traded down $0.01 during trading hours on Thursday, hitting $6.04. 2,398,931 shares of the company were exchanged, compared to its average volume of 1,554,745. The company has a 50 day moving average of $5.02 and a two-hundred day moving average of $5.32. Vir Biotechnology, Inc. has a 52-week low of $4.16 and a 52-week high of $14.45. The firm has a market cap of $839.08 million, a price-to-earnings ratio of -1.51 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The company had revenue of $1.21 million for the quarter, compared to analysts' expectations of $2.38 million. During the same quarter last year, the company earned ($1.02) EPS. Vir Biotechnology's revenue for the quarter was down 60.5% compared to the same quarter last year. On average, equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Institutional Trading of Vir Biotechnology

A number of large investors have recently made changes to their positions in the company. Squarepoint Ops LLC lifted its position in Vir Biotechnology by 99.9% during the 2nd quarter. Squarepoint Ops LLC now owns 107,360 shares of the company's stock worth $541,000 after acquiring an additional 53,662 shares during the period. Hudson Bay Capital Management LP lifted its position in Vir Biotechnology by 17.7% during the 2nd quarter. Hudson Bay Capital Management LP now owns 696,000 shares of the company's stock worth $3,508,000 after acquiring an additional 104,580 shares during the period. Public Sector Pension Investment Board lifted its position in Vir Biotechnology by 7.4% during the 2nd quarter. Public Sector Pension Investment Board now owns 314,176 shares of the company's stock worth $1,583,000 after acquiring an additional 21,598 shares during the period. Corient Private Wealth LLC lifted its position in Vir Biotechnology by 100.7% during the 2nd quarter. Corient Private Wealth LLC now owns 518,684 shares of the company's stock worth $2,614,000 after acquiring an additional 260,308 shares during the period. Finally, Captrust Financial Advisors lifted its position in Vir Biotechnology by 39.7% during the 2nd quarter. Captrust Financial Advisors now owns 30,739 shares of the company's stock worth $155,000 after acquiring an additional 8,739 shares during the period. 65.32% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Evercore ISI started coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $12.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Monday, September 15th. Weiss Ratings reissued a "sell (e+)" rating on shares of Vir Biotechnology in a research report on Saturday, September 27th. Bank of America raised Vir Biotechnology from a "neutral" rating to a "buy" rating and raised their target price for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Finally, Raymond James Financial started coverage on Vir Biotechnology in a research report on Friday, July 11th. They set an "outperform" rating on the stock. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $17.30.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.